agile trial: frontline axitinib versus sorafenib in metastatic renal cell carcinoma
Published 11 years ago • 485 plays • Length 3:57Download video MP4
Download video MP3
Similar videos
-
11:26
axis trial: second-line axitinib versus sorafenib in metastatic renal cell carcinoma
-
2:16
dr. rini on axitinib for treatment of metastatic renal cell carcinoma
-
1:19
dr. nicholas vogelzang on first-line axitinib versus sorafenib in mrcc
-
1:12
dr. rini describes axitinib's and sorafenib's side effects
-
0:43
dr. rini on the results from his axitinib and sorafenib trial
-
6:36
frontline clinical trials in renal cell carcinoma
-
0:38
dr. rini explains the axitinib integration process
-
12:21
intorsect trial: second-line temsirolimus versus sorafenib in renal cell carcinoma
-
2:11
dr. cella discusses axitinib and sorafenib axis trial
-
8:31
second-line angiogenesis inhibition in metastatic renal cell carcinoma
-
0:44
dr. rini on the axitinib and sorafenib trial vegf focus
-
9:52
phase 3 axitinib data in patients with previously treated advanced renal cell carcinoma
-
8:57
introduction and review of the comparz trial in renal cell carcinoma
-
3:36
first-line treatment of poor-risk metastatic renal cell carcinoma
-
0:43
dr. rini discusses the vegf targeted agent axitinib
-
1:03
dr. hutson discusses the phase iii atlas study in rcc
-
1:37
dr. shuch on caveats of avelumab/axitinib combination in rcc
-
3:05
imbrave150: updated data on atezo plus bev versus sorafenib in hcc
-
0:44
real-world efficacy of avelumab and axitinib in advanced renal cell carcinoma